Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 24;5(1):274.
doi: 10.1038/s41392-020-00401-6.

SERIneALanine Killer: SPT promiscuity inhibits tumour growth via intra-tumoral deoxysphingolipid production

Mattia Falcone  1 , Oliver D K Maddocks  2
Affiliations
Comment

SERIneALanine Killer: SPT promiscuity inhibits tumour growth via intra-tumoral deoxysphingolipid production

Mattia Falcone et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

O.D.K.M. contributed to the CRUK Cancer Research Technology’s filing of Patent Application no. WO2017144877A1, and is a co-founder and shareholder of Faeth Therapeutics Inc.

Figures

Fig. 1
Fig. 1
SPT promiscuity links intra-tumoral serine and alanine metabolism to sphingolipid heterogeneity in cancer cells. Schematic diagram depicting sphingolipid synthesis under normal (left, blue) and low serine (red, right) conditions. Under normal conditions serine palmitoyltransferase (SPT) synthesises sphingosine (SO) as the canonical precursor of dihydroceramide (DHCER), ceramide (CER) and ultimately complex membrane lipids. Under low serine conditions alanine is an SPT substrate, fuelling synthesis of 1-deoxysphinganine (deoxySA), which is further metabolised into 1-deoxydihydroceramide (deoxyDHCER) and 1-deoxyceramide (deoxyCER), altering membrane lipid diversity and impairing tumour growth
See this image and copyright information in PMC

Comment on

References

    1. Muthusamy T, et al. Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature. 2020;586:790–795. doi: 10.1038/s41586-020-2609-x. - DOI - PMC - PubMed
    1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308. doi: 10.1016/j.ccr.2012.02.014. - DOI - PMC - PubMed
    1. Tajan M, Vousden KH. Dietary approaches to cancer therapy. Cancer Cell. 2020;37:767–785. doi: 10.1016/j.ccell.2020.04.005. - DOI - PubMed
    1. Maddocks ODK, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544:372–376. doi: 10.1038/nature22056. - DOI - PubMed
    1. Newman AC, Maddocks ODK. Serine and functional metabolites in cancer. Trends Cell Biol. 2017;27:645–657. doi: 10.1016/j.tcb.2017.05.001. - DOI - PubMed

Publication types